Akèy › Twoub depresif majè › Ohio
Etid klinik pou Twoub depresif majè nan Ohio
29 etid pou Twoub depresif majè ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Oct 1, 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT06559306A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
Ap rekriteFaz 3
Laj 12 a 17 · Tout sèks · Mizajou Sep 25, 2026 · NCT07227454Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT05850689Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Sep 24, 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Sep 14, 2026 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Sep 8, 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
Ap rekrite
Laj 22 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06423430Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
Ap rekrite
Laj 18 a 65 · Tout sèks · Mizajou Aug 19, 2026 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Aug 10, 2026 · NCT07592689Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
Ap rekriteFaz 1/2
Laj 18 a 60 · Tout sèks · Mizajou Aug 3, 2026 · NCT06795451A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
Ap rekriteFaz 3
Laj 18 a 74 · Tout sèks · Mizajou Aug 3, 2026 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
Ap rekriteFaz 2
Laj 18 a 64 · Tout sèks · Mizajou Aug 3, 2026 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
Ap rekriteFaz 2
Laj 18 a 64 · Tout sèks · Mizajou Jul 27, 2026 · NCT07115329Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou Jul 24, 2026 · NCT07484217Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 24, 2026 · NCT06966401A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
Ap rekriteFaz 2
Laj 21 a 65 · Tout sèks · Mizajou Jul 23, 2026 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Jun 15, 2026 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou May 11, 2026 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
Ap rekrite
Laj 14 a 18 · Tout sèks · Mizajou Feb 11, 2026 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Jan 20, 2026 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
Ap rekrite
Laj 14 a 17 · Tout sèks · Mizajou Aug 11, 2025 · NCT03859297Study of ALTO-300 in MDD
- Site 202, Cincinnati
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 24, 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Jan 23, 2025 · NCT06223880Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.